Abstract:The mechanism of DNA alkylation by mitomycin C, an anti cancer agent, as well as factors governing formation, synthesis and stereochemical configuration of DNA adducts generated by this compound are presented, with a focus on recent developments. The biological role of each DNA adduct in the drug's cytotoxicity is discussed in correlation with the DNA structural modifications they induce. Mitomycin C, (MC), an antitumor drug used in the clinics, is a DNA alkylating agent. Inert in its native form, MC is reduced to reactive mitosenes in cellulo which undergo nucleophilic attack by DNA bases to form monoadducts as well as interstrand crosslinks (ICLs). These properties constitute the molecular basis for the cytotoxic effects of the drug. The mechanism of DNA alkylation by mitomycins has been studied for the past 30 years and, until recently, the consensus was that drugs of the mitomycins family mainly target CpG sequences in DNA. However, that paradigm was recently challenged. Here, we relate the latest research on both MC and dicarbamoylmitomycin C (DMC), a synthetic derivative of MC which has been used to investigate the regioselectivity of mitomycins DNA alkylation as well as the relationship between mitomycins reductive activation pathways and DNA adducts stereochemical configuration. We also review the different synthetic routes to access mitomycins nucleoside adducts and oligonucleotides containing MC/DMC DNA adducts located at a single position. Finally, we briefly describe the DNA structural modifications induced by MC and DMC adducts and how site specifically modified oligonucleotides have been used to elucidate the role each adduct plays in the drugs cytotoxicity.

DNA Adducts in Cancer Chemotherapy

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy

DNA or Not DNA —that is the Question Determining the Design of Platinum Anticancer Drugs

Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy

Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand

Study on the Interactions Between Anti-Cancer Drug Oxaliplatin and DNA

DNA Damage and Its Role in Cancer Therapeutics

Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA

Insight Into Factors Governing Formation, Synthesis and Stereochemical Configuration of DNA Adducts formed by Mitomycins

Single-Molecule Force Spectroscopy of Deoxyribonucleic Acid and Deoxyribonucleic Acid Polymerase Activity Impacted by Alkylating Agents

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Effects of Dietary Phytochemicals on DNA Damage in Cancer Cells

Biosynthesis of DNA-Alkylating Antitumor Natural Products

Proteomic Analysis of Cisplatin- and Oxaliplatin-Induced Phosphorylation in Proteins Bound to Pt-DNA Adducts.

DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action

Identification and Characterization of DNA-Oxaliplatin Adducts through α-hemolysin Nanopores

Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies

Intercalation Ability of Novel Monofunctional Platinum Anticancer Drugs: A Key Step in Their Biological Action

Unraveling and Overcoming Platinum Drug‐Resistant Cancer Tumors with DNA Nanostructures